Thrombin-activatable fibrinolysis inhibitor aka procarboxypeptidase U
Source
Haemostasis and thrombosis: basic principles and clinical practice / Colman [edit.]-p. 381-394
Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate
Source
Analytical biochemistry - ISSN 0003-2697-340:1 (2005) p. 106-112
Different effects of low-dose transdermal and oral oestrogen therapy on procarboxypeptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study
Source
Thrombosis and haemostasis : international journal for vascular biology and medicine - ISSN 0340-6245-93:3 (2005) p. 620-622
HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis: a randomized, placebo-controlled study in postmenopausal women
Source
Journal of thrombosis and haemostasis - ISSN 1538-7933-3:5 (2005) p. 1090-1092
Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease
Source
Thrombosis and haemostasis : international journal for vascular biology and medicine - ISSN 0340-6245-94:3 (2005) p. 471-487